We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Advancis Pharmaceutical Corporation, a pharmaceutical company focused on developing and commercializing novel anti-infective products, announced that the United States District Court for the District of Delaware has issued an opinion and order in favor of sanofi-aventis ruling that Advancis is infringing the sanofi-aventis trademark.
Barr Pharmaceuticals, Inc. announced that its subsidiary, Barr Laboratories, Inc., has launched a generic version of Cephalon Inc.'s ACTIQ (oral transmucosal fentanyl citrate) [C-II], 200 mcg, 400 mcg, 600 mcg, 800 mcg, 1200 mcg, and 1600 mcg cancer pain management treatment product.
Pharmacopeia, an innovator in the discovery and development of novel small molecule therapeutics, announced an agreement to extend its collaboration with Schering-Plough until April of 2007.
Amgen announced Amgen Oncology Assistance (AOA), a comprehensive, multi-faceted financial assistance program that will include a "cap" on out-of-pocket co-payments for cancer patients receiving Vectibix (panitumumab).
Barr Pharmaceuticals, Inc. announced that the Hart-Scott-Rodino ("HSR") waiting period for the company's acquisition of Shire plc's ADDERALL (immediate-release mixed amphetamine salts) product has expired without further action from the U.S. Federal Trade Commission ("FTC").
Reliant Pharmaceuticals failed to disclose any risk information in two promotional pieces for its Rythmol SR extended-release capsules and suggested that the product is effective for more indications than those approved by the FDA, the agency said in a warning letter to the company.
Several healthcare issues are beginning to make headway in Congress, with drug importation, biodefense and National Institutes of Health (NIH) legislation taking important steps toward becoming law in the past week.
Cellegy Pharmaceuticals, Inc. announced that it has entered into an agreement with Strakan International Limited, a wholly owned subsidiary of ProStrakan Group plc, a publicly-traded company based in the United Kingdom, under which ProStrakan will acquire Cellegy's rights to Cellegesic (nitroglycerin ointment), which is branded Rectogesic outside of the United States, Fortigel (testosterone gel), Tostrex (testosterone gel), and Tostrelle (testosterone gel), and related intellectual property assets.